General
Preferred name
TRIMEBUTINE
Synonyms
TRIMEBUTINE MALEATE ()
Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester ()
Debridat ()
Polibutin ()
Mebutin ()
Trimebutine (maleate) ()
3, 4, 5-Trimethoxybenzoic Acid 2-(Dimethylamino)-2-phenylbutyl Ester Maleate Salt ()
Trimebutina ()
P&D ID
PD009062
CAS
39133-31-8
58997-91-4
34140-59-5
58997-92-5
58997-89-0
Tags
available
drug
Drug indication
Irritable bowel syndrome
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Trimebutine maleate is an orally anti-tumor agent. Trimebutine maleate selectively suppresses stemness and proliferation of ovarian cancer stem cells (CSCs). Trimebutine maleate reduces the colonic muscle hypercontractility, modulates gastrointestinal motility, induces apoptosis and can be used for the research of glioma/glioblastoma and irritable bowel syndrome[1][2][3][4][5][6].
PRICE
29
PRICE
29
DESCRIPTION
Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.
DESCRIPTION
Trimebutine maleate (Polibutin) is a weak mu-opioid agonist and has antimuscarinic effects. Trimebutine is an agonist of peripheral mu, delta, and kappa opiate receptors served as a spasmolytic drug for therapy of both chronic and acute abdominal pain.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Trimebutine (Mebutin) is a spasmolytic agent that regulates intestinal and colonic motility and relieves abdominal pain with antimuscarinic and weak mu-opioid agonist effects. It is marketed for the treatment of irritable bowel syndrome (IBS) and lower gastrointestinal tract motility disorders, with IBS being one of the most common multifactorial GI disorders. It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form. Trimebutine is not an FDA-Approved/Clinical drug, but it is available in Canada and several other international countries.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
63
Molecular Weight
387.2
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
9
Ring Count
2
Aromatic Ring Count
2
cLogP
3.74
TPSA
57.23
Fraction CSP3
0.41
Chiral centers
1.0
Largest ring
6.0
QED
0.61
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Calcium Channel
Opioid Receptor
Akt
Apoptosis
ERK
IRAK
JNK
NF-κB
Potassium Channel
Toll-like Receptor (TLR)
Oct3/4
Pathway
GPCR/G protein
Immunology/Inflammation
MAPK/ERK Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
PI3K/Akt/mTOR
Stem Cell/Wnt
Endocrinology/Hormones
Metabolism
Neuroscience
Source data
